The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases

Cited by (135)

Items 101–135 of 135

1. Synthesis and Bioevaluation of 2-Styrylquinoxaline Derivatives as Tau-PET Tracers.
   Nan Wu, Longfei Zhang, Xiao-Jun Zhang, Qilei Zhang, Jia‐Qi Liu, Yu-Ying Li, Xiao-Xin Yan, Yingying Liang, Jin-Ming Zhang, M. Cui · 2023 · Molecular Pharmaceutics
2. Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects
   M. Miyamoto, C. Okuyama, S. Kagawa, Kuninori Kusano, Masaaki Takahashi, K. Takahata, M. Jang, H. Yamauchi · 2023 · Annals of Nuclear Medicine
3. Structure-activity relationship around PI-2620 highlights the importance of the nitrogen atom position in the tricyclic core.
   Heiko Kroth, F. Oden, A. Serra, Jerome Molette, A. Mueller, M. Berndt, F. Capotosti, Emanuele Gabellieri, H. Schmitt-Willich, D. Hickman et al. · 2021 · Bioorganic & Medicinal Chemistry
4. Synthesis and evaluation of 2-pyrrolopyridinylquinoline derivatives as selective tau PET tracers for the diagnosis of Alzheimer's disease.
   P. Lerdsirisuk, R. Harada, Y. Hayakawa, Yuki Shimizu, Y. Ishikawa, R. Iwata, Yukitsuka Kudo, N. Okamura, S. Furumoto · 2020 · Nuclear Medicine and Biology
5. In vivo imaging of tau deposition in Alzheimer’s disease using both [18F]-THK5317 and [18F]-S16: A pilot human study
   L. Fu, Jinming Zhang, Kai-Xiang Zhou, Xiao-Jun Zhang, Hengge Xie, Ming-Wei Zhu, M. Cui, Rui-Min Wang · 2022 · Frontiers in Aging Neuroscience
6. Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
   Elisa Colato, Alzheimer’s Disease Neuroimaging Initiative, Konstantinos Chiotis, Daniel Ferreira, Mariam S. Mazrina, Laëtitia Lemoine, Rosaleena Mohanty, Eric Westman, Agneta K. Nordberg, Elena Rodriguez‐Vieitez · 2021 · Journal of Alzheimer s Disease
7. Molecular Imaging of Extrapyramidal Movement Disorders with Dementia: The 4R Tauopathies
   K. Frey · 2021 · Seminars in nuclear medicine
8. Tau positron emission tomography in patients with cognitive impairment and suspected Alzheimer’s disease
   H. Matsuda, Tensho Yamao · 2023 · Fukushima Journal of Medical Science
9. Structure–Activity Relationships and Evaluation of 2-(Heteroaryl-cycloalkyl)-1H-indoles as Tauopathy Positron Emission Tomography Radiotracers
   Jeffrey S. Stehouwer, Guofeng Huang, Dinahlee Saturnino Guarino, Manik L. Debnath, Ashok Polu, Steven J. Geib, Brian J. Lopresti, Miloš D. Ikonomović, Neale Scott Mason, Robert H. Mach et al. · 2025 · Journal of Medicinal Chemistry
10. The Monoamine Oxidase‐B Inhibitor Selegiline Does Not Affect 18F‐Florzolotau Uptake in Patients with Progressive Supranuclear Palsy: A Longitudinal Case Series
    Xin-Yi Li, Fang-Yang Jiao, Rui-Xin Yao, Z. Ju, Mingjia Chen, J. Ge, Gen Li, Yi-Min Sun, Ping Wu, Jian-Jun Wu et al. · 2023 · Movement Disorders
11. Tracers progress for positron emission tomography imaging of glial-related disease
    Haoran Jia, Tianwu Xie · 2022 · Journal of Biomedical Research
12. Discovery of 2-(4-(2-fluoroethoxy)piperidin-1-yl)-9-methyl-9H-pyrrolo[2,3-b:4,5-c']dipyridine ([18F]PI-2014) as PET tracer for the detection of pathological aggregated tau in Alzheimer's disease and other tauopathies.
    Emanuele Gabellieri, F. Capotosti, Jerome Molette, N. Sreenivasachary, A. Mueller, M. Berndt, Hanno Schieferstein, Tanja Juergens, Yvan Varisco, F. Oden et al. · 2020 · European journal of medicinal chemistry
13. PET markers of tau and neuroinflammation are co-localized in progressive supranuclear palsy
    M. Malpetti, L. Passamonti, T. Rittman, P. Jones, P. Vasquez-Rodriguez, W. R. Bevan-Jones, Young T. Hong, T. Fryer, F. Aigbirhio, J. O'Brien et al. · 2019
14. Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?
    R. Mito, D. Raffelt, Thijs Dhollander, D. Vaughan, Jacques-Donald Tournier, Olivier Salvado, A. Brodtmann, C. Rowe, V. Villemagne, A. Connelly · 2018 · Brain : a journal of neurology
15. Distinct 11C-ER176 PET Neuroinflammatory Profiles and Tau Colocalization in Progressive Apraxia of Speech With and Without Parkinson-plus Syndrome
    Ryota Satoh, Rene L. Utianski, Joseph R. Duffy, Heather M. Clark, Yehkyoung C. Stephens, Jeyeon Lee, Matt C. Baker, Rosa Rademakers, Val J. Lowe, Keith A. Josephs et al. · 2025 · Clinical Nuclear Medicine
16. Evaluation of advanced, pathophysiologic new targets for imaging of CNS
    Priya Singh, Deepika Singh, P. Srivastava, Gauri Mishra, A. K. Tiwari · 2023 · Drug development research (Print)
17. Tauopathy in the APP swe / PS1 ΔE9 mouse model of familial Alzheimer’s disease
    Athanasios Metaxas, Camilla Thygesen, Stefan J. Kempf, M Anzalone, Ramanan Vaitheeswaran, Sussanne Petersen, Anne Marlene Landau, Hélène Audrain, Jessica L. Teeling, Sultan Darvesh et al. · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
18. PET and SPECT Imaging of Neurodegenerative Diseases
    Alexander E. Drzezga, Gérard N. Bischof, Kathrin Giehl, Thilo van Eimeren · 2021 · Elsevier eBooks
19. Joint EANM/SNMMI recommendations on the use of Tau PET imaging in Alzheimer's disease
    Matthias Brendel, Phillip H. Kuo, Joachim Brumberg, Vincent Doré, Alexander E. Drzezga, Valentina Garibotto, Antoine Leuzy, Gregory Mathoux, Philipp Tobias Meyer, Alexis Moscoso et al. · 2026 · The EANM Journal
20. Partial volume effect correction impairs the diagnostic utility of [18F]-THK-5351 PET in nonfluent-agrammatic variant primary progressive aphasia
    Patrick Sommer, S. Schuster, O. Goldhardt, Nobuyuki Okamura, F. Mueller-Sarnowski, Maximilian Scheifele, F. Eckenweber, Annika Kreuzer, Maria Griessl, P. Bartenstein et al. · 2025 · NeuroImage: Clinical
21. Head-to-head comparison of relative cerebral blood flow derived from dynamic [18F]florbetapir and [18F]flortaucipir PET in subjects with subjective cognitive decline
    H. Tuncel, D. Visser, T. Timmers, E. Wolters, R. Ossenkoppele, W. M. van der Flier, B. N. van Berckel, R. Boellaard, S. Golla · 2023 · EJNMMI Research
22. Synthesis and Evaluation of Radioiodinated [125I]7‐Iodo‐5H‐Pyrido[4,3‐B]Indole ([125I]CTAU) in Postmortem Human Alzheimer's Disease Brain
    Chloe C McNamara, Agnes P Biju, Emma Hipolito, Ngan-Hanh-Thao Nguyen, Christopher Liang, J. Mukherjee · 2026 · Journal of labelled compounds & radiopharmaceuticals
23. In Situ Labeling of Pathogenic Tau Using Photo-Affinity Chemical Probes
    Pengju Nie, You Wu, John L. Robinson, Shekar Mekala, Virginia M.‐Y. Lee, Yue‐Ming Li · 2025 · ACS Chemical Biology
24. Molecular Imaging of Neurodegenerative Parkinsonism.
    K. Frey, N. Bohnen · 2021 · PET Clinics
25. Nuclear Medicine-Based Diagnosis and Therapeutic Strategies for Neurodegenerative Diseases: Clinical Progress.
    Yi Li, Ke Pu, De-Qiang Li, Yi-Jin Zhao, Qi-Xin Cai, Xin Zhou, Shao-Qing Li, Yue Chen, Zhi-Jun Zhou, Yang Liu · 2026 · Ageing Research Reviews
26. The importance of tau tracers in the diagnosis of neurodegenerative diseases
    Sara Sadeghian, S. Seradj · 2026 · Results in Chemistry
27. Molecular Dynamics Study of the Binding of Cationic, Anionic, and Neutral Luminescent Conjugated Ligands to the Alzheimer Folds of Aβ(1–42) and Tau Fibrils
    Yogesh Todarwal, Mathieu Linares, Patrick Norman · 2026 · ChemBioChem
28. Selective imaging probes for differential detection of pathological tau polymorphs in tauopathies.
    Nicolò Bisi, Luca Pinzi, G. Rastelli · 2025 · Drug Discovery Today
29. Tau-PET Bildgebung der Bewegungsstörungen
    L. Beyer, M. Brendel · 2022 · Angewandte Nuklearmedizin
30. Corticobasal Degeneration
    M. Niethammer · 2021 · Hybrid PET/MR Neuroimaging
31. Amyloid deposition, tau aggregation and microglial activation in Alzheimer's disease: a PET study
    M. Dani · 2017
32. Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development
    Yiyun Henry Huang, Hongmei Jia, Weiqi Bao · 2020 · Elsevier eBooks
33. New PET radiopharmaceuticals for imaging CNS diseases
    Joachim Brumberg, Andrea Varrone · 2021 · Elsevier eBooks
34. The role of tau and neuroinflammation in Progressive Supranuclear Palsy and Alzheimer's Disease
    Patricia Vázquez Rodríguez · 2019 · Apollo (University of Cambridge)
35. PET Biomarkers for Tau Pathology
    Antoine Leuzy, Kerstin Heurling, Michael Schöll · 2019 · Springer eBooks